Seattle Genetics is a biotechnology company focused on the development and commercialization of empowered monoclonal antibody–based therapies for the treatment of cancer. Their product, brentuximab vedotin (Adcetris), was granted FDA accelerated approval in August 2011 for 2 indications: the treatment of patients with Hodgkin lymphoma after failure of autologous stem [ Read More ]
Thomas C. Reynolds, MD, PhD
Chief Medical Officer
Dr Reynolds joined Seattle Genetics in March 2007 as Chief Medical Officer. Dr Reynolds has more than 15 years of biotechnology drug development experience, from preclinical development through the FDA approval process. Dr Reynolds holds a BA in chemistry from Dartmouth College and an MD as well as a PhD in biophysics from Stanford University.